Found: 7
Select item for more details and to access through your institution.
Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.
- Published in:
- European Journal of Haematology, 2019, v. 102, n. 6, p. 494, doi. 10.1111/ejh.13231
- By:
- Publication type:
- Article
CML-129: OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S328, doi. 10.1016/S2152-2650(21)01769-9
- By:
- Publication type:
- Article
Poster: CML-129: OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S223, doi. 10.1016/S2152-2650(21)01408-7
- By:
- Publication type:
- Article
Oral Abstract: CML-129: OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S202, doi. 10.1016/S2152-2650(21)01274-X
- By:
- Publication type:
- Article
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
- Published in:
- 2020
- By:
- Publication type:
- journal article
The Oral Proteasome Inhibitor Ixazomib in Combination with Melphalan-Prednisone (MP) for Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 1/2 Dose-Escalation Study (NCT01335685).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S337, doi. 10.1016/j.clml.2017.07.153
- By:
- Publication type:
- Article
A phase 1 open-label study to assess the relative bioavailability of TAK-931 tablets in reference to powder-in-capsule in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2023, v. 41, n. 1, p. 53, doi. 10.1007/s10637-022-01318-3
- By:
- Publication type:
- Article